- Home
- ADIL vs VIRX Comparison
ADIL vs VIRX Comparison
Compare ADIL & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- VIRX
- Stock Information
- Founded
- ADIL 2010
- VIRX 2007
- Country
- ADIL United States
- VIRX United States
- Employees
- ADIL N/A
- VIRX N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- VIRX Health Care
- Exchange
- ADIL Nasdaq
- VIRX Nasdaq
- Market Cap
- ADIL 6.5M
- VIRX 7.0M
- IPO Year
- ADIL 2018
- VIRX N/A
- Fundamental
- Price
- ADIL $0.96
- VIRX $0.17
- Analyst Decision
- ADIL Strong Buy
- VIRX Buy
- Analyst Count
- ADIL 1
- VIRX 4
- Target Price
- ADIL $8.00
- VIRX $5.00
- AVG Volume (30 Days)
- ADIL 86.8K
- VIRX 2.3M
- Earning Date
- ADIL 11-13-2024
- VIRX 03-06-2025
- Dividend Yield
- ADIL N/A
- VIRX N/A
- EPS Growth
- ADIL N/A
- VIRX N/A
- EPS
- ADIL N/A
- VIRX N/A
- Revenue
- ADIL N/A
- VIRX N/A
- Revenue This Year
- ADIL N/A
- VIRX N/A
- Revenue Next Year
- ADIL N/A
- VIRX N/A
- P/E Ratio
- ADIL N/A
- VIRX N/A
- Revenue Growth
- ADIL N/A
- VIRX N/A
- 52 Week Low
- ADIL $0.77
- VIRX $0.13
- 52 Week High
- ADIL $4.17
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- ADIL 37.57
- VIRX 44.76
- Support Level
- ADIL $0.99
- VIRX $0.15
- Resistance Level
- ADIL $1.06
- VIRX $0.19
- Average True Range (ATR)
- ADIL 0.06
- VIRX 0.03
- MACD
- ADIL -0.01
- VIRX -0.00
- Stochastic Oscillator
- ADIL 0.00
- VIRX 21.00
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.